Ralpancizumab
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke[1].
Product Specifications
CAS Number
1407495-04-8
UNSPSC
12352203
Target
PCSK9
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ralpancizumab.html
Purity
96.23
Solubility
10 mM in DMSO
Smiles
[Ralpancizumab]
Molecular Weight
(145.28 kDa)
References & Citations
[1]Sanz-Cuesta BE, et al. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. Stroke. 2021 Oct;52 (10) :3142-3150.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC941531-100 1x 100 µL
IL3RA / CD123 (Acute Myeloid Leukemia Marker) (IL3RA/1531), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680680-500 1x 500 µL
Cyclin B1 (V92.1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470925-500 1x 500 µL
Mucin 1 / EMA / Episialin / CD227 (139H2), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details